Disease · MONDO_0002271

colon adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. colon adenocarcinoma. Diseases, record MONDO_0002271. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002271

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: colon adenocarcinoma; Open Targets
Open Targets ID: MONDO_0002271; Open Targets
Other names: adenocarcinoma - colon, adenocarcinoma of colon, adenocarcinoma of the colon, colonic adenocarcinoma; Open Targets
Disease Ontology: DOID:234; Disease Ontology
NCI Thesaurus: C4349; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 11 of its 35 drugs, from ClinicalTrials.gov; Open Targets

Drugs35

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 35

See all 35 drugs

Targets50

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP1	DNA topoisomerase 1	2	DNA topoisomerase I inhibitor	Phase 3	https://conductscience.org/library/genes/7150	Drugs and targets
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
ABL1	Tyrosine-protein kinase ABL1	1	Tyrosine-protein kinase ABL inhibitor	Phase 1	https://conductscience.org/library/genes/25	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CSNK1E	Casein kinase I isoform epsilon	1	Casein kinase I epsilon inhibitor	Phase 1	https://conductscience.org/library/genes/1454	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
CXCL8	Interleukin-8	1	Interleukin-8 inhibitor	Phase 2	https://conductscience.org/library/genes/3576	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets

1 to 10 of 50

See all 50 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00265850	Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Phase 3	2,334	2017-04-26	Colorectal Cancer	BEVACIZUMAB, CETUXIMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00001880	Stem Cell Transplantation for Metastatic Solid Tumors	Phase 2	42	2021-11-10	Neoplasm Metastasis	CYCLOSPORINE, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT00091312	Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Phase 3	1,976		Colorectal Cancer	FLUOROURACIL, IRINOTECAN, LEUCOVORIN	Its record names the disease	ClinicalTrials.gov
NCT00427310	Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery	Phase 3	1,158		Colorectal Cancer	FLUOROURACIL, HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT06783491	Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer	Phase 3	1,083		Locally Advanced Colorectal Cancer	FLUOROURACIL, LEUCOVORIN, MITOMYCIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02355379	Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over	Phase 3	774		Colonic Adenocarcinoma	CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT03026140	Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer	Phase 2	353		Colon Carcinoma	ADAKITUG, CELECOXIB, IPILIMUMAB, NIVOLUMAB, RELATLIMAB	Its record names the disease	ClinicalTrials.gov
NCT01167725	Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer	Phase 3	340		Colorectal Cancer	BEVACIZUMAB, CAPECITABINE, CETUXIMAB, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01285037	A Study of LY2801653 in Advanced Cancer	Phase 1	190		Cancer	CETUXIMAB, CISPLATIN, GEMCITABINE, MERESTINIB, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT00201331	Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	Phase 2	162		Colonic Diseases, Adenocarcinoma	FLUOROURACIL, LEUCOVORIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events	98 of 559	111 of 578	1,137	NCT00265850

Source Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
17553204	RESULT	1	PubMed
16356309	RESULT	1	PubMed
42906564	DERIVED	1	PubMed
41115454	DERIVED	1	PubMed
39278994	DERIVED	1	PubMed
38838316	DERIVED	1	PubMed
38838311	DERIVED	1	PubMed
38457761	DERIVED	1	PubMed
36067452	DERIVED	1	PubMed
34606846	DERIVED	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002271

GET https://conductscience.org/api/diseases/v1/MONDO_0002271/drugs?page=2

API reference For AI assistants